Seelos Therapeutics, Inc. (SEELQ)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Aug 1, 2025, 4:00 PM EDT

Seelos Therapeutics Company Description

Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders.

The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease.

Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York. On November 16, 2024, Seelos Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.

Seelos Therapeutics, Inc.
CountryUnited States
Founded2016
IndustryBiotechnology
SectorHealthcare
Employees16
CEORaj Mehra

Contact Details

Address:
300 Park Avenue
New York, Nevada 10022
United States
Phone646 293 2100
Websiteseelostherapeutics.com

Stock Details

Ticker SymbolSEELQ
ExchangeOTCMKTS
Stock TypeCommon Stock
Fiscal YearJanuary - December
Reporting CurrencyUSD
SIC Code2836

Key Executives

NamePosition
Dr. Raj Mehra J.D., Ph.D.Chief Executive Officer, Founder, President and Chairman
Michael J. GolembiewskiChief Financial Officer
Anthony MarcianoChief Communications Officer
Gopal Krishna Ph.D.Head of Manufacturing and Technical Operations
Tim Whitaker M.D.Chief Medical Officer
Karen FusaroSenior Vice President and Head of Clinical Operations